Premiums outstrip medical costs for first time in 6 years










It's no secret that health plan premiums are up sharply. Last year marked the first time since HMOs' go-go period in the early- to mid-'90s that premium increases were higher than the increase in underlying medical costs. When medical costs slowed in the mid '90s, premium hikes did, too — but the rates of increase often fell below those of medical-cost inflation because of health plans' desire to grab market share. Now, after many lean years in the health plan industry, rising medical costs have forced plans to adopt what would appear to be a more sound pricing structure — one that covers medical costs and administration. In this round of escalating medical costs, though, the margin between premium increases and medical-cost inflation is far smaller than was typical in the early '90s, perhaps again due to competitive pressures.

Yet again, bigger is better

Whether this pricing tactic helps health plans return to profitability remains to be seen, but it appears the industry's financial picture is brightening. Data from Interstudy Publications reveal that average profit (in these cases, loss) levels improved, from –3.2 percent in 1998 to –1.3 percent in 1999. Operating margins were poorer for HMOs in small markets (fewer than 250,000 people) than in large markets (more than 1 million).

SOURCES: CENTER FOR STUDYING HEALTH SYSTEM CHANGE, WASHINGTON, NOVEMBER 2000; REGIONAL MARKET ANALYSIS 10.2, INTERSTUDY PUBLICATIONS, MINNEAPOLIS, NOVEMBER 2000

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.